Insight & Intelligence

More »

September 1, Vol. 32, No. 15

  • Columns

    • Bold Predictions for Future Cancer Tests
    • Winny Tan, Ph.D.
    • Physicians depend on tests for cancer biomarkers at various disease stages to help them diagnose, monitor, predict treatment or prognosis, and also predict risk for their patient’s particular cancer Laboratory testing for cancer biomarkers spans multiple clinical detection platforms and ... more »
    • Tackling the Problems of Insolubility
    • Carol Potera
    • Companies developing biotherapeutics face the challenge of how to keep therapeutic proteins soluble, stable, and active About half of all recombinant proteins are insoluble, a major hurdle for advancing them through drug discovery pipelines and into clinical trials Unlike small ... more »
    • Ocular Therapeutics Target the Retina
    • Gail Dutton
    • Treatments for retinal diseases are expected to overtake those of glaucoma by 2014, “making retinal disease the most lucrative sector of the ophthalmic drugs market, overtaking the glaucoma sector,” according to the report, “Macular Degeneration (AMD) and Diabetic Retinopathy (DR): ... more »
    • People in the News
    • Paul Chapman is now president and CEO of Quanterix Previously, Chapman was vp of BioPharm Process Solutions at EMD Millipore Additionally, Chapman’s experience includes being international business development manager at Roche Molecular Diagnostics... more »

Be sure to take the GEN Poll

{{ vm.poll.Title }}

More »